How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

542 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

381. Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial

but previously treated with placebo in the L-FMAU-301, L-FMAU-302. Patients who were currently receiving antiviral, immunomodulatory or corticosteroid therapy. Patients previously treated with interferon, lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection. Patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy. Patients co-infected with HCV, HDV or HIV. Patients with a liver mass (hemangioma, nodule), biliary diseases except

2006 Clinical Trials

382. Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection

with the study requirements. Exclusion Criteria: Patient is currently receiving antiviral, immunomodulatory or corticosteroid therapy. Patients previously treated with lamivudine, lobucavir, adefovir, famciclovir, or any other investigational nucleoside for HBV infection. Previous treatment with interferon must have ended at least 6 months prior to the screening visit. Patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy. Patient is co-infected with HCV or HIV. Patient has evidence

2006 Clinical Trials

383. Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)

of reference range Serum creatinine >1.5 times upper limit of reference range Haemoglobin < 11g/dL WBC count <3x10^9/L Platelets <100x10^9 Serious concurrent medical illness other than hepatitis B Use of immunosuppressive therapy, immunomodylatory therapy or chronic antiviral thgerpay with other agents within the previous 6 months or during the study Previous treatment with lamivudine or famciclovir within the last 6 months History of hypersensitivity to nucleoside analogues Women of childbearing potential

2006 Clinical Trials

384. Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis

or 3 months or more after completion of any antiviral treatment (eg. famciclovir, lamivudine etc.), and the patient has not had interferon therapy or any antiviral therapy between the biopsy and screening. Liver biopsy showing advance fibrosis/cirrhosis (Ishak fibrosis score ≥4). The slides must be available for review by an independent histopathologist. Availability and willingness of the subject to provide written informed consent per ICH/GCP and local Guidelines. Exclusion Criteria: ALT >10XULN

2006 Clinical Trials

385. HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.

history of adverse reaction to valacyclovir, acyclovir or famciclovir; Planned open label use of acyclovir, valacyclovir, or famciclovir Known medical history of seizures Known renal failure, serum creatinine >2.0mg/dl Hematocrit < 30 % Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2006 Clinical Trials

386. Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2)

Initiating HAART per Peruvian guidelines for the first time at study entry CD4 count less than 200 cells/mm3 OR CD4 count less than 350 cells/mm3 AND viral load greater than 55,000 copies/ml within 30 days prior to study entry Does not intend to move outside of greater metropolitan Lima, Peru area for the duration of the study Willing to follow all study requirements Willing to provide written informed consent Exclusion Criteria: Prior HAART History of adverse reaction to acyclovir, famciclovir (...) , or valacyclovir Unwilling to take acyclovir, famciclovir, or valacyclovir History of seizures Renal insufficiency, defined as serum creatinine greater than 2 mg/dl or a creatinine clearance less than 50 ml/min Treatment for a serious medical condition 14 days prior to study entry. Patients with chronic, acute, or recurrent opportunistic infections (OIs) who have completed therapy and are clinically stable on therapy for at least 14 days prior to study entry are not excluded. Clinically unstable and untreated

2006 Clinical Trials

387. Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients

medications during the 12 month observation period of the study are: Virustatic drugs, active against CMV: Foscarnet, Cidofovir (HPMPC), Acyclovir, Valaciclovir, Famciclovir/Penciclovir, Lobucavir, Antisense compound Antimetabolites: Fluorouracil, Mercaptopurine, Methotrexate, Thioguanine, Hydroxurea Alkylating substances: Busulfan, Carmustine, Chlorambucil, Cisplatin, Cyclophosphamide, Dacarbazine (DTIC), Lomustine, Mechlormethamine, Melphalan, Streptozotocin, Tiothepa, Uracil mustard anti CMV

2006 Clinical Trials

388. Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

(except for systemic acyclovir, valacyclovir and famciclovir), cytotoxic drugs, investigational drugs, or any drugs known to have major organ toxicity. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00189293 Locations Layout table for location

2005 Clinical Trials

389. Suppression of Oral HHV8 Shedding With Valganciclovir

drugs with known anti-HHV-8 activity for study duration able to comply with the study protocol agree to HIV testing Exclusion Criteria: history of evidence of CMV disease hypersensitivity to ganciclovir or valganciclovir use of high-dose acyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, or cidofovir neutropenia renal insufficiency with serum creatinine greater than 1.5mg.ml or CrCl less than 60 AST or ALT greater than 5 times upper limit of normal concurrent administration of medications

2005 Clinical Trials

390. HBsAg Seroclearance in Chinese Patients Receiving Lamivudine Therapy for Chronic Hepatitis B Virus Infection Full Text available with Trip Pro

HBsAg Seroclearance in Chinese Patients Receiving Lamivudine Therapy for Chronic Hepatitis B Virus Infection We report two Chinese patients in whom lamivudine treatment resulted in HBsAg seroclearance. One patient received lamivudine, and another patient received 12-week famciclovir treatment followed by lamivudine. Lamivudine was maintained after HBeAg seroconversion. These two patients lost HBsAg at 24 and 27 months (ages, 23 and 19.3 years, respectively) and developed measurable titer

2004 Journal of clinical microbiology

391. Chickenpox Full Text available with Trip Pro

relating to the effectiveness and safety of the following interventions: acyclovir, famciclovir, live attenuated vaccine, valaciclovir, varicella zoster immunoglobulin, and zoster immunoglobulin.

2007 BMJ Clinical Evidence

392. [Effect of Huangbai Liquid on expression of human beta-defensin-2 mRNA in skin lesions of patients with recurrent genital herpes]. (Abstract)

[Effect of Huangbai Liquid on expression of human beta-defensin-2 mRNA in skin lesions of patients with recurrent genital herpes]. To investigate the expression of human beta-defensin-2 (HBD-2) mRNA in skin lesions of patients with recurrent genital herpes (RGH) and the effect of Huangbai Liquid (HL) on it.Twenty-seven patients were randomly assigned to 2 groups, the HL group (n = 14) treated with HL and the famciclovir group (n = 13) with famciclovir. HBD-2 expression of patients were detected (...) before and after the treatment and compared with that of 10 healthy subjects.HBD-2 expression was found in the skin lesions of both the healthy persons and the RGH patients before treatment. It is higher significantly in the HL group than in the famciclovir group after treatment.HL was suitable for treatment of RGH since it could improve immune function of RGH patients and keep a rather higher concentration of HBD-2 expression in local skin lesions.

2006 Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban Controlled trial quality: uncertain

393. Single-day therapy for recurrent genital herpes. (Abstract)

evaluated the effectiveness of patient-initiated single-day famciclovir versus placebo in the treatment of genital herpes and found that single-day famciclovir decreased healing time and the duration of pain and other symptoms, and increased the proportion of patients who did not progress to a full outbreak. Compared with previous studies, the results of single-day therapy are similar to or better than the results of conventional therapies of 2-5 days' duration. In addition, the convenience of single

2006 American journal of clinical dermatology Controlled trial quality: uncertain

394. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. (Abstract)

nucleoside antivirals that are extensively eliminated by renal excretion. Potential interactions with stavudine and famciclovir were evaluated in single-dose studies, whereas interactions with zidovudine and its major metabolite, zidovudine glucuronide, were evaluated in a multiple-dose study. Plasma pharmacokinetic profiles and, in some studies, urinary excretion data were evaluated when each drug was administered alone and in combination with emtricitabine. Safety and plasma pharmacokinetic profiles

2007 Journal of clinical pharmacology Controlled trial quality: uncertain

395. Live, attenuated varicella zoster vaccination of an immunocompromised patient. Full Text available with Trip Pro

), a diagnosis of disseminated cutaneous herpes zoster was made. The patient was treated successfully with a course of famciclovir for 10 days and cephalexin for 7 days for a secondary bacterial infection. A review of the medical literature disclosed no reports of Zostavax given to adult cancer patients immunocompromised by systemic chemotherapy. Therefore, we believe this report is the first to describe the consequences of Zostavax administration to such a host. Clinicians should take care to review

2008 Journal of General Internal Medicine

396. The treatment of herpes simplex infections: an evidence-based review. Full Text available with Trip Pro

The treatment of herpes simplex infections: an evidence-based review. Genital and labial herpes simplex virus infections are frequently encountered by primary care physicians in the United States. Whereas the diagnosis of this condition is often straightforward, choosing an appropriate drug (eg, acyclovir, valacyclovir hydrochloride, or famciclovir) and dosing regimen can be confusing in view of (1) competing clinical approaches to therapy; (2) evolving dosing schedules based on new research

2008 Archives of Internal Medicine

397. The prevention and management of herpes zoster. (Abstract)

The prevention and management of herpes zoster. The burden of illness from herpes zoster (HZ) and postherpetic neuralgia (PHN) in the Australian community is high. The incidence and severity of HZ and PHN increase with age in association with a progressive decline in cell-mediated immunity to varicella-zoster virus (VZV). Antiviral medications (valaciclovir, famciclovir, aciclovir) have been shown to be effective in reducing much but not all of the morbidity associated with HZ and PHN

2008 Medical Journal of Australia

398. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. (Abstract)

prophylactically to all symptomatic myeloma patients.A retrospective review of the records of 125 myeloma patients who were treated with bortezomib and who also received routine acyclovir prophylaxis at the dose of 400 mg daily in >80% of patients was undertaken. Alternatives, used in <20% of patients, were 200 mg of acyclovir, 250/500 mg of valacyclovir, or 500 mg of famciclovir administered daily. This was accompanied by patient education regarding the importance of compliance with these prophylactic

2008 Cancer

399. Herpes zoster antivirals and pain management. (Abstract)

searching by pertinent topics, authors, and journals.If started within 72 hours of the onset of the acute HZ rash, the oral antiviral agents acyclovir, valacyclovir, and famciclovir significantly shorten the periods of acute pain, virus shedding, rash, acute and late-onset anterior segment complications, and, in the case of valacyclovir and famciclovir, the incidence and severity of PHN. However, these medications do not prevent PHN, which remains a common and debilitating complication of HZ in older

2008 Ophthalmology

400. Atypical herpes simplex infection masquerading as recalcitrant pemphigus vulgaris. (Abstract)

. Dramatic resolution was observed and the patient has remained free of disease for 13 months while taking only prophylactic famciclovir.

2007 Australasian Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>